Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 in Solid Tumors Patients
NCT05620472Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Carrier/Scaffold Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of [99mTc]Tc(CO)3-(HE)3-Ec1 in solid tumor (3 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body [99mTc]Tc(CO)3-(HE)3-Ec1 uptake value at 24 hours, SPECT-based [99mTc]Tc(CO)3-(HE)3-Ec1 value in tumor lesions at 6 hours and 2 more. Started Oct 2022; status: completed.
02
Drugs
[99mTc]Tc(CO)3-(HE)3-Ec1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05620472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620472.